Anti-U1RNP antibodies in patients with localized scleroderma

Archives of Dermatological Research

Volumn 293, Issue 9, 2001, Pages 455-459

  Yamane, Kenichi ^a   Ihn, H ^a   Kubo, Masahide ^a   Kuwana, Masataka ^b   Asano, Yoshihide ^a   Yazawa, Norihito ^a   Tamaki, Kunihiko ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Autoantibody; Immunoblotting; Immunoprecipitation

Indexed keywords

CELL EXTRACT; NUCLEAR RNA; RIBONUCLEOPROTEIN ANTIBODY; SMALL NUCLEAR RIBONUCLEOPROTEIN;

ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ANTIGEN SPECIFICITY; ARTICLE; BLOOD SAMPLING; CELL NUCLEUS; CONTROLLED STUDY; HELA CELL; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; LARYNX TUMOR; MAJOR CLINICAL STUDY; MIXED CONNECTIVE TISSUE DISEASE; MORPHEA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SYSTEMIC SCLEROSIS; TUMOR CELL;

AUTOANTIBODIES; CHILD; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOBLOTTING; IMMUNODIFFUSION; PRECIPITIN TESTS; REFERENCE VALUES; RIBONUCLEOPROTEIN, U1 SMALL NUCLEAR; SCLERODERMA, LOCALIZED; SCLERODERMA, SYSTEMIC;

EID: 0034750347     PISSN: 03403696     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004030100254     Document Type: Article

References (28)

1. When is scleroderma not scleroderma?
2. Antinuclear antibodies in localized scleroderma
3. Juvenile linear scleroderma associated with serological abnormalities
4. Linear scleroderma: Clinical spectrum, prognosis, and laboratory abnormalities
5. Anti-single-strand DNA antibody and muscle involvement in localized scleroderma
6. Antihistone antibodies in localized scleroderma
7. Demonstration of interleukin-2, interleukin-4 and interleukin-6 in sera from patients with localized scleroderma
8. Clinical significance of serum levels of soluble interleukin-2 receptor in patients with localized scleroderma
9. Increased levels of circulating intercellular adhesion molecule-1 in patients with localized scleroderma
10. Demonstration of interleukin 8 in serum samples of patients with localized scleroderma
11. Increased serum levels of soluble vascular cell adhesion molecule 1 and E-selectin in patients with localized scleroderma
12. Antinuclear antibodies: Diagnostic markers for autoimmune diseases and probes for cell biology
13. Mixed connective tissue disease - An apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA)
14. Distribution and antigen specificity of anti-U1RNP antibodies in patients with systemic sclerosis
15. Racial differences in the distribution of systemic sclerosis-related serum antinuclear antibodies
16. Profiles of antinuclear antibodies in systemic rheumatic diseases
17. Antibodies to small nuclear RNAs complexed with proteins are produced by patients with systemic lupus erythematosus
18. The structure of mammalian small nuclear ribonucleo-proteins
19. Splicing of messenger RNA precursors is inhibited by antisera to small nuclear ribonucleoprotein
20. The use of immunoblotting and immunoprecipitation of (U) small nuclear ribonucleoproteins in the analysis of sera of patients with mixed connective tissue disease and systemic lupus erythematosus. A cross-sectional, longitudinal study
21. Identification of human Sm and (U1) RNP antigens by immunoblotting
22. Antibodies against distinct nuclear matrix proteins are characteristic for mixed connective tissue disease
23. Preliminary criteria for the classification of systemic sclerosis (scleroderma)
24. Oncostatin M stimulates transcription of the human α2(I) collagen gene via the Sp1/Sp3-binding site
25. Prevalence and antigen specificity of anti-histone antibodies in patients with polymyositis/dermatomyositis
26. Are snRNPs involved in splicing?
27. The U1 small nuclear RNA-protein complex selectively binds a 5′ splice site in vitro
28. The 5′ terminus of the RNA moiety of U1 small nuclear ribonucleoprotein particles is required for the splicing of messenger RNA precursors